



(51) **International Patent Classification:**
C07K 16/28 (2006.01) *C07K 16/32* (2006.01)

(21) **International Application Number:**
PCT/EP2020/080941

(22) **International Filing Date:**
04 November 2020 (04.11.2020)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
19206959.9 04 November 2019 (04.11.2019) EP

(71) **Applicant: NUMAB THERAPEUTICS AG [CH/CH];**
Einsiedlerstrasse 34, 8820 Wädenswil (CH).

(72) **Inventors: URECH, David;** Sonnenblickstrasse 8, 8645 Jona (CH). **HESS, Christian;** Uetlibergstrasse 304, 8045 Zurich (CH). **SIMONIN, Alexandre;** 5 rue de l'Au, 68128 Rosenau (FR). **WARMUTH, Stefan;** Zopfstrasse 28, 8804 Au (CH).


(74) **Agent: WALLINGER RICKER SCHLOTTER TOST-MANN;** Patent- und Rechtsanwälte, Partnerschaft mbB, Zweibrückenstraße 5-7, 80331 Munich (DE).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) **Title:** MULTISPECIFIC ANTIBODY

Figure 13:



(57) **Abstract:** The present invention relates to a multispecific antibody comprising at least one domain specifically binding to a tumor-associated immune checkpoint antigen with low affinity, and at least one domain specifically binding to a tumor-associated antigen (TAA), and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*